Abstract
BALF IL-6 and blood CRP levels, and ESR may have the ability for discriminating disease severity in hospitalized children with CAP, whereas WBC count and ANC have limited ability. No biomarkers or cytokines seemed to have the ability to predict the pathogen category, while BALF IL-6, blood ANC, and ESR may assist in the diagnosis of single MP, bacteria, and virus infections, respectively.
Introduction
Community-acquired pneumonia (CAP) remains a leading cause of pediatric hospitalization and mortality worldwide. For clinicians, the primary challenge is risk stratification: quickly determining which children have a mild infection and which are at risk for severe complications requiring intensive intervention. Currently, practitioners often rely on systemic biomarkers like White Blood Cell (WBC) counts or Absolute Neutrophil Counts (ANC). However, these markers can be inconsistent, sometimes showing normal levels even in severe cases. This study investigates whether cytokines, specifically Interleukin-6 (IL-6) found directly in the lungs via bronchoalveolar lavage fluid (BALF), provide a more accurate diagnostic tool than traditional blood tests.
Methods
The researchers conducted a retrospective study of 118 children hospitalized with CAP. All patients underwent bronchoscopy within the first 48 hours of admission to collect BALF. Blood samples were also taken to measure standard markers (WBC, ANC, CRP, ESR) and systemic IL-6. Patients were divided into three severity tiers: Mild (no complications), Moderate (mild-to-moderate complications), and Severe (severe complications or organ failure). The team used Receiver Operating Characteristic (ROC) curves and Area Under the Curve (AUC) analysis to determine which biomarkers best discriminated between severity levels.
Key Results
Severity Prediction and Biomarker Performance
The study found that the local inflammatory response in the lung tissue is distinct from the systemic response, as there was no significant correlation between IL-6 levels in the blood and the lungs. Among all tested markers, BALF IL-6 was the standout performer for identifying disease severity.
Statistical analysis confirmed that BALF IL-6 demonstrated an AUC of 0.847 for discriminating severe cases from non-severe cases, with a high sensitivity of 0.917. In contrast, standard WBC and ANC tests had limited ability to discriminate disease severity.
Hospitalization and Pathogens
While BALF IL-6 is excellent for assessing immediate severity, blood-based C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR) were the best predictors of the total length of hospital stay. Regarding pathogen identification, BALF IL-6 was significantly higher in Mycoplasma pneumoniae infections, while blood ANC was more indicative of bacterial infections.
Discussion and Limitations
While BALF IL-6 is a superior marker, its clinical utility is currently limited to patients already requiring a bronchoscopy due to the invasive nature of the procedure. Furthermore, as a retrospective single-center study, these findings require validation through larger prospective trials. The authors suggest that future research should explore whether IL-6 levels could guide the use of corticosteroids or other immunomodulatory therapies in severe pediatric pneumonia cases.
Summary updated